A New Targeted Therapy for Certain Blood Cancers
The FDA approved zanubrutinib, a second-generation Bruton’s tyrosine kinase inhibitor. The U.S. Food and Drug Administration (FDA) has approved...
Progress Against Cancer
The FDA approved zanubrutinib, a second-generation Bruton’s tyrosine kinase inhibitor. The U.S. Food and Drug Administration (FDA) has approved...
The FDA granted accelerated approval to mosunetuzumab-axgb, the first bispecific antibody approved to treat a form of non-Hodgkin lymphoma. ...
The FDA approved the adenovirus-based gene therapy nadofaragene firadenovec for the treatment of localized bladder cancer. The U.S. Food...
A second inhibitor of the difficult-to-target KRAS protein was approved to treat certain lung cancers. The U.S. Food and...
The FDA approved the PD-L1 inhibitor atezolizumab to treat alveolar soft part sarcoma The U.S. Food and Drug Administration...
A second inhibitor of mutant IDH1 was approved to treat certain blood cancers. The U.S. Food and Drug Administration...
A targeted therapy was approved for a subset of treatment-resistant ovarian, fallopian tube, and peritoneal cancers. The U.S. Food...
The FDA approved the immune checkpoint inhibitor tremelimumab to treat certain patients with non-small cell lung cancer. The U.S....
The CD30-targeted antibody-drug conjugate was approved for some children with blood cancer. The U.S. Food and Drug Administration (FDA)...
The immune checkpoint inhibitor cemiplimab-rwlc was approved in combination with chemotherapy for certain patients with non-small cell lung cancer. ...